Baseline characteristics and treatment of patients hospitalised with
4.7 (252) · € 11.00 · En stock
Full article: Predicting In-Hospital Treatment Failure (≤7 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids
Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial
Results Modules: Baseline Characteristics
Burden and Impact of Toxicities on Outcomes for Aggressive B Cell Non-Hodgkin Lymphoma Patients after CD19-Directed Chimeric Antigen Receptor T Cell: Real-World Experience - Biology of Blood and Marrow Transplantation
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial - The Lancet Respiratory Medicine
Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials - eClinicalMedicine
These highlights do not include all the information needed to use MULTAQ safely and effectively. See full prescribing information for MULTAQ. MULTAQ® (dronedarone) tablets, for oral use Initial U.S. Approval: 2009
First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease
Incomplete Reporting of Baseline Characteristics in Clinical Trials: An Analysis of Randomized Controlled Trials and Systematic Reviews Involving Patients with Chronic Low Back Pain
Early thrombocytopenia is associated with an increased risk of mortality in patients with traumatic brain injury treated in the intensive care unit: a Finnish Intensive Care Consortium study
Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype
Cureus, Cytomegalovirus Reactivation in Patients With Acute Lymphoblastic Leukemia in Non-transplant Setting
Frontiers Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
Abstract WMP4: Intravenous Thrombolysis Before Endovascular Treatment Leads to Higher Hospital Charges Without Improving Outcomes
